Physician profile
Michael A Williams
NPI 1679542740
$3,068.60
in general payments reported to CMS, 2019-2025
23 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $659 · 2021: $785 · 2022: $358 · 2023: $342 · 2024: $281 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $846.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $450.23 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.75 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $255.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $193.92 | 2022-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $192.99 | 2019-2022 | |
| Amgen INC. | $145.14 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $118.50 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $107.13 | 2020-2024 | Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $97.25 | 2023-2025 | |
| Pfizer INC. | $63.60 | 2020-2025 | |
| Abbvie INC. | $63.23 | 2023-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $41.18 | 2021 | |
| Eisai INC. | $37.07 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $32.93 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $27.20 | 2022 | |
| Horizon Therapeutics Plc | $25.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2022 | |
| Exact Sciences Corporation | $14.88 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $13.69 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $13.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.11 | 2021 | |
| Dexcom, INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.